|
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer
RECRUITINGPhase 3Sponsored by University College, London
Actively Recruiting
PhasePhase 3
SponsorUniversity College, London
Started2026-06-29
Est. completion2030-12
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07831902
Summary
RAINBO NSMP-ORANGE aims to investigate if adjuvant radiotherapy with oral progestin tablets is as effective as radiotherapy with chemotherapy, whilst reducing toxicity and thus improving quality of life, in patients with high-risk NSMP endometrial cancer. Patients will be randomised to radiotherapy with chemotherapy (standard of care), or radiotherapy followed by oral progestin tablets.
Eligibility
Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria: 1. Written informed consent and consent for data sharing for the overarching RAINBO programme 2. Histologically confirmed diagnosis of endometrial cancer (EC) of the following histotypes: endometrioid endometrial carcinoma, serous endometrial carcinoma, uterine clear cell carcinoma, dedifferentiated and undifferentiated endometrial carcinoma, uterine carcinosarcoma and mixed endometrial carcinomas of the aforementioned histotypes 3. Full molecular classification performed following the diagnostic algorithm described in WHO 2020 (5th Edition, IARC, Lyon, 2020, adapted from Vermij et al. 2020) 4. Hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy or sentinel node biopsy, without macroscopic residual disease after surgery 5. No distant metastases as determined by pre-surgical or post-surgical imaging (CT scan of chest, abdomen and pelvis within 8 weeks of randomisation). Whole-body PET-CT scan is acceptable if this is part of standard of care at participating sites 6. Age ≥ 18 years 7. WHO performance status 0 or 1 8. Expected start of adjuvant treatment within 10 weeks after surgery 9. Patients must be accessible for treatment and follow-up 10. Consent for the donation of a tissue block for translational research for the overarching RAINBO programme 11. FIGO (2018) stage II EC with substantial LVSI or stage III NSMP tumours 12. p53 wildtype, MMR proficient EC with no somatic pathogenic POLE variant (i.e. NSMP) 13. ER+ by IHC (10% threshold applied) or Allred score of ≥3 14. Absolute neutrophil count (ANC) ≥1.5 x 109 /l 15. Platelets ≥ 100 x 109 /L 16. Bilirubin ≤ 1.5 x UNL (or ≤ 3 x ULN for cases of known Gilbert's syndrome) 17. AST/ALT ≤ 2.5 x UNL Exclusion Criteria: 1. Previous malignancy, except for non-melanoma skin cancer, in the past 5 years 2. Prior pelvic radiation 3. Active or recent arterial thromboembolic disease (e.g. angina, myocardial infarction) within previous 6 months 4. Thromboembolic event, e.g. pulmonary embolism or deep vein thrombosis, within previous 6 months 5. Impaired renal function: ≤50ml/min (EDTA clearance, or measured creatinine clearance) or creatinine clearance ≤60 ml/min (calculated according to Cockcroft gault) 6. Uncontrolled cardiac disease (defined as cardiac function which would preclude hydration during cisplatin administration and any contraindication to paclitaxel) 7. Peripheral neuropathy, ≥ grade 2 8. Inflammatory bowel disease 9. Known history of porphyria 10. History of active immune deficiency syndromes or uncontrolled HIV infection: HIV positive patients receiving effective antiretroviral therapy and CD4 count \>200 may be included 11. Patients who have received a live attenuated vaccine within 2 weeks prior to planned treatment start 12. Any other condition which as per section 4.3 of the relevant SmPC or in the opinion of the investigator contraindicates the use of chemotherapy, radiotherapy and/or oral progestin tablets 13. The patient is currently participating in another interventional clinical trial or has received an investigational drug (either approved or not approved) in any prior clinical study within 5 half-lives prior to screening
Conditions3
CancerEndometrial CancerUterine Neoplasms
Interventions3
Related trials
- A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients — Shenyang Sunshine Pharmaceutical Co., LTD.
- Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer — The Netherlands Cancer Institute
- Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer — Karolinska University Hospital
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer — AstraZeneca
- A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors — Mabwell (Shanghai) Bioscience Co., Ltd.
- A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer — Shanghai Jiao Tong University School of Medicine
- A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer — Xianglin Yuan
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorUniversity College, London
Started2026-06-29
Est. completion2030-12
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07831902